Current
—
5-Year Average
—
All-Time High
—
All-Time Low
—
P/FCF Ratio daily chart for Relmada Therapeutics (RLMD)
Jul 28, 2021 – Jul 27, 2026 · 1,254 trading days
P/FCF ratio is not shown for periods when TTM free cash flow was negative.
Historical P/FCF Ratio for Relmada Therapeutics (RLMD) from 2012 to 2025
| 2025 | $330M | -$45.8M | — | — | |
| 2024 | $15.7M | -$51.8M | — | — | |
| 2023 | $31M | -$51.7M | — | — | |
| 2022 | $26.3M | -$104M | — | — | |
| 2021 | $86.1M | -$91.9M | — | — | |
| 2020 | $104M | -$27.8M | — | — | |
| 2019 | $88.7M | -$12.1M | — | — | |
| 2018 | $5.88M | -$8.72M | — | — | |
| 2017 | $1.88M | -$5.01M | — | — | |
| 2016 | $2.62M | -$10.2M | — | — | |
| 2015 | $5.71M | -$16.1M | — | — | |
| 2014 | $31.5M | -$7.33M | — | — | |
| 2013 | $17.1M | -$24.3K | — | — | |
| 2012 | $17.1M | — | — | — |
- 2025—
- 2024—
- 2023—
- 2022—
- 2021—
- 2020—
- 2019—
- 2018—
- 2017—
- 2016—
- 2015—
- 2014—
- 2013—
- 2012—
About P/FCF Ratio at Relmada Therapeutics (RLMD)
The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.
Sector peers by P/FCF Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/FCF Ratio — table
Healthcare peers of Relmada Therapeutics (RLMD), ranked by P/FCF ratio.
| 17.8× | |
| 17.8× | |
| 16.9× | |
| 16.9× | |
| 16.7× | |
| 16.4× | |
| 15.9× | |
| 15.9× | |
| 14.5× | |
| 14.0× | |
| 13.4× | |
| 12.9× | |
| 12.4× | |
| 12.2× | |
| 12.1× | |
| 11.3× | |
| 11.3× | |
| 10.4× | |
| 10.3× | |
| 9.6× | |
| 9.1× | |
| 9.1× | |
| 6.9× | |
| 3.9× | |
| 2.5× |
- 17.8×
- 16.9×
- 16.7×
- 16.4×
- 14.5×
- 12.9×
- 12.4×
- 11.3×
- 10.3×
- 9.1×
- 9.1×
- 6.9×
- 2.5×
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric